Outlook Therapeutics (OTLK) Long-Term Investments (2020 - 2026)
Outlook Therapeutics (OTLK) posted quarterly Long-Term Investments of $468430.0 for Q1 2026, down 24.87% year-over-year from $623486.0 in Q1 2025, and down 8.79% quarter-over-quarter from $513549.0 in Q4 2025.
Outlook Therapeutics (OTLK) Long-Term Investments (2020 - 2026) Analysis & Trends
Outlook Therapeutics (OTLK) has reported Long-Term Investments for 7 consecutive years, with $468430.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Long-Term Investments fell 24.87% year-over-year to $468430.0; the TTM figure through Mar 2026 stood at $468430.0 (down 24.87% YoY), while the FY2025 annual figure was $552183.0, down 20.34% from the prior year.
- Long-Term Investments retreated to $468430.0 in Q1 2026 per OTLK's latest filing, from $513549.0 in the prior quarter.
- Across five years, Long-Term Investments topped out at $826435.0 in Q4 2022 and bottomed at $468430.0 in Q1 2026.
- Historically, Long-Term Investments has averaged $708662.0 across 5 years, with a median of $765885.0 in 2024.
- Annual changes were most pronounced in 2022 — Long-Term Investments surged 74.79% — and 2026, when it declined 24.87%.
- Outlook Therapeutics' Long-Term Investments stood at $826435.0 in 2022, then fell by 3.62% to $796480.0 in 2023, then fell by 17.15% to $659895.0 in 2024, then retreated by 22.18% to $513549.0 in 2025, then fell by 8.79% to $468430.0 in 2026.
- Business Quant data shows OTLK's Long-Term Investments at $468430.0 in Q1 2026, $513549.0 in Q4 2025, and $552183.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Long-Term Investments (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 5.79 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 9.83 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 1.77 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 22.17 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 372.10 Mn |
| 10 | Outlook Therapeutics | 88.50 Mn | 77.26 Mn | -8,265.00 | 2.53 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 468,430.00 |
| Dec 31, 2025 | 513,549.00 |
| Sep 30, 2025 | 552,183.00 |
| Jun 30, 2025 | 592,602.00 |
| Mar 31, 2025 | 623,486.00 |
| Dec 31, 2024 | 659,895.00 |
| Sep 30, 2024 | 693,190.00 |
| Jun 30, 2024 | 708,388.00 |
| Mar 31, 2024 | 765,885.00 |
| Dec 31, 2023 | 796,480.00 |
| Sep 30, 2023 | 793,932.00 |
| Jun 30, 2023 | 802,282.00 |
| Mar 31, 2023 | 809,470.00 |
| Dec 31, 2022 | 826,435.00 |
| Sep 30, 2022 | 804,930.00 |
| Jun 30, 2022 | 812,156.00 |
| Mar 31, 2022 | 823,961.00 |
| Dec 31, 2021 | 830,005.00 |
| Sep 30, 2021 | 853,660.00 |
| Jun 30, 2021 | 464,654.00 |